Trial Profile
A phase II trial of PXS-4728A in patients with non-alcoholic steatohepatitis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs BI 1467335 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
- 06 Sep 2017 Status changed from planning to recruiting, according to a Pharmaxis media release.
- 23 May 2017 New trial record